Management of inflammatory bowel diseases in the wake of COVID-19 pandemic

J Gastroenterol Hepatol. 2020 Aug;35(8):1449-1450. doi: 10.1111/jgh.15056. Epub 2020 Apr 26.

Authors

Syed Bilal Pasha¹, Huda Fatima², Yezaz A Ghouri³

Affiliations

¹ Department of Medicine, University of Missouri-School of Medicine at Columbia, Columbia, Missouri, USA.
² Dow Medical College, Karachi, Pakistan.
³ Department of Medicine-Division of Gastroenterology and Hepatology, University of Missouri-School of Medicine at Columbia, Columbia, Missouri, USA.

PMID: 32246874
DOI: 10.1111/jgh.15056

No abstract available

Publication types

Letter

MeSH terms

Betacoronavirus / isolation & purification
COVID-19
Comorbidity
Coronavirus Infections* / epidemiology
Coronavirus Infections* / prevention & control
Humans
Immunosuppressive Agents* / administration & dosage
Immunosuppressive Agents* / adverse effects
Infection Control / methods
Inflammatory Bowel Diseases* / epidemiology
Inflammatory Bowel Diseases* / therapy
Medication Therapy Management
Pandemics* / prevention & control
Patient Acuity
Patient Selection
Pneumonia, Viral* / epidemiology
Pneumonia, Viral* / prevention & control
SARS-CoV-2

Substances

Immunosuppressive Agents